SEOUL, South Korea--(BUSINESS WIRE)--Macrogen (KOSDAQ: 038290), the Korean precision medicine biotech company, is hosting a ‘Now, Get A Free Knock-out Mouse!’ event on a first-come, first-served basis.
The ‘Now, Get A Free Knock-out Mouse’ is Macrogen’s first ambitious launching event of GEM (Genetically-Engineered Mice)-related product offering to overseas customers. To celebrate this, the event will be provided to researchers in the United States, Europe, and Asia (excluding some Asian countries). When customers apply for Macrogen's CRISPR KO Mouse service, they can receive a KO (Knock-Out) mouse for free, which is over $10,000. The event will be held from March 1 to June 30.
KO is a technique that removes or transforms certain genes to produce KO mice with new characteristics. Macrogen utilizes the CRISPR gene-editing technology to provide KO Mouse in a faster and more efficient way. Currently, KO mouse is widely used throughout the world in the non-clinical phase of new drug development, safety, and validation.
This event was made possible by Macrogen’s advanced technology developed for the sperm cryopreservation. The improved technology enabled Macrogen to ship the frozen sperms of the GEM rather than shipping live animals, which is very hard and costly. Compared with the existing sperm cryopreservation technology, the enhanced technology has increased the research efficiency by 30% by improving the birth rate from the fertilized eggs by frozen sperm. Macrogen manufactures the disease model mouse requested by the customer, and then collects the sperm of the mouse and delivers it to the customer in a cryopreserved state. Customers can use cryopreserved sperm and the protocols provided to reproduce mice with much higher efficiency.
Macrogen is Korea's only GEM manufacturing company with facilities ranging from GEM custom-made services to SPF (Specific Pathogen Free). The company is the top company producing the largest number of the model animals in Korea. Macrogen has been providing disease model mice since 1997 and has 23 years of expertise. The company also acquired the license of CRISPR-Cas9 gene-editing technology from Broad Institute in the United States in 2018 and has been using the technology for producing model mice with enhanced productivity.